HealthCare Global Enterprises Ltd. (IN:HCG)
:HCG
Top Page
HealthCare Global Enterprises Ltd.
(HCG)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹574.00
▼(-12.43% Downside)
Action:ReiteratedDate:10/23/25
HealthCare Global Enterprises Ltd. benefits from strong technical momentum and solid financial performance, but its high P/E ratio suggests overvaluation. The lack of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Sustained revenue growth
Consistent double-digit top-line growth indicates expanding patient volumes and utilization across HCG’s oncology network. That trend supports longer-term capacity absorption, improves leverage on fixed clinical costs, and underpins durable cash generation over the next 2–6 months.
Negative Factors
High financial leverage
Near-2.0 debt/equity means capital structure relies heavily on borrowings. For a capital-intensive healthcare provider, elevated leverage raises interest and refinancing risk and constrains strategic flexibility for new high-cost oncology equipment or M&A over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Consistent double-digit top-line growth indicates expanding patient volumes and utilization across HCG’s oncology network. That trend supports longer-term capacity absorption, improves leverage on fixed clinical costs, and underpins durable cash generation over the next 2–6 months.
Read all positive factors
HealthCare Global Enterprises Ltd. (HCG) vs. iShares MSCI India ETF (INDA)
Market Cap
₹80.41B
Dividend YieldN/A
Average Volume (3M)18.12K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth17.58%
EPS Growth-38.20%
CountryIN
Employees6,150
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.10
Shares Outstanding149,302,200
10 Day Avg. Volume16,611
30 Day Avg. Volume18,118
Financial Highlights & Ratios
PEG Ratio-21.26
Price to Book (P/B)7.99
Price to Sales (P/S)3.31
P/FCF Ratio68.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹728.00Price Target Upside11.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)9.43
Revenue Forecast (FY)₹29.58B
HealthCare Global Enterprises Ltd. Business Overview & Revenue Model
Company Description
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertil...
How the Company Makes Money
HCG primarily makes money by delivering healthcare services to patients across its hospital and cancer-center network. Its key revenue streams include: (1) inpatient and outpatient clinical care fees for consultations, procedures, surgeries, chemo...
HealthCare Global Enterprises Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
68
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.02B | 22.23B | 19.12B | 16.94B | 13.98B | 10.13B |
| Gross Profit | 11.85B | 11.91B | 10.48B | 9.20B | 7.52B | 5.27B |
| EBITDA | 3.72B | 3.13B | 2.67B | 2.37B | 1.78B | 656.22M |
| Net Income | 353.60M | 444.10M | 481.55M | 293.49M | 537.33M | -1.93B |
Balance Sheet | ||||||
| Total Assets | 35.86B | 35.43B | 27.07B | 23.16B | 22.20B | 20.36B |
| Cash, Cash Equivalents and Short-Term Investments | 2.02B | 3.53B | 3.03B | 1.97B | 2.04B | 1.66B |
| Total Debt | 17.68B | 18.37B | 12.74B | 9.01B | 9.15B | 9.78B |
| Total Liabilities | 25.92B | 25.53B | 18.42B | 14.47B | 13.36B | 13.22B |
| Stockholders Equity | 9.21B | 9.22B | 8.26B | 8.61B | 8.70B | 6.97B |
Cash Flow | ||||||
| Free Cash Flow | 339.30M | 1.08B | 988.99M | 1.18B | 1.49B | 850.97M |
| Operating Cash Flow | 1.92B | 3.17B | 2.85B | 2.52B | 2.20B | 1.21B |
| Investing Cash Flow | -580.00M | -4.88B | -2.26B | -1.33B | 1.25B | -1.71B |
| Financing Cash Flow | -806.50M | -424.40M | -640.16M | -1.40B | -1.55B | 1.12B |
HealthCare Global Enterprises Ltd. Technical Analysis
Negative
655.45
Price Trends
573.09
Negative
636.06
Negative
634.13
Negative
Market Momentum
-14.17
Positive
40.15
Neutral
27.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HCG, the sentiment is Negative. The current price of 655.45 is above the 20-day moving average (MA) of 546.75, above the 50-day MA of 573.09, and above the 200-day MA of 634.13, indicating a bearish trend. The MACD of -14.17 indicates Positive momentum. The RSI at 40.15 is Neutral, neither overbought nor oversold. The STOCH value of 27.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:HCG.
HealthCare Global Enterprises Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹344.42B | 75.82 | ― | 0.24% | 14.72% | 8.37% | |
67 Neutral | ₹80.41B | -247.47 | ― | ― | 17.58% | -38.20% | |
66 Neutral | ₹906.72B | 84.46 | ― | 0.14% | 32.17% | 28.12% | |
65 Neutral | ₹277.85B | 83.79 | ― | 0.04% | 15.78% | 15.01% | |
62 Neutral | ₹347.24B | 151.95 | ― | 0.84% | -36.14% | -93.99% | |
61 Neutral | ₹610.08B | 86.12 | ― | 0.11% | 15.33% | 54.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:HCG
HealthCare Global Enterprises Ltd.
538.55
21.65
4.19%
IN:ASTERDM
Aster DM Healthcare Ltd.
670.20
197.49
41.78%
IN:FORTIS
Fortis Healthcare Ltd.
808.10
176.50
27.94%
IN:MAXHEALTH
Max Healthcare Institute Ltd
931.75
-142.41
-13.26%
IN:MEDANTA
Global Health Limited
1,033.70
-161.67
-13.52%
IN:NH
Narayana Hrudayalaya Ltd.
1,685.35
46.86
2.86%
HealthCare Global Enterprises Ltd. Corporate Events
HCG Extends Timeline for Additional 34% Stake Purchase in Vizag Cancer Hospital
Mar 29, 2026
HealthCare Global Enterprises Ltd. has signed second amendment agreements to its Share Purchase Agreement and Shareholders’ Agreement related to the acquisition of Vizag Hospital and Cancer Research Centre Private Limited. The amendments pri...
HealthCare Global Expands Equity Base with ₹512-Per-Share Rights Allotment
Mar 27, 2026
HealthCare Global Enterprises Ltd., a Bengaluru-based oncology-focused hospital chain with operations across India and in Kenya, has expanded its equity base through a recently completed rights issue to existing shareholders. The company provides ...
HealthCare Global Clears Rights Issue Offer to Raise Up to ₹424.7 Crore
Feb 24, 2026
HealthCare Global Enterprises Ltd. has finalized and filed its Letter of Offer for a rights issue of up to 8,294,566 fully paid equity shares, each with a face value of ₹10 priced at ₹512 including premium, to raise up to ₹42,468...
HCG Posts Double-Digit Revenue and EBITDA Growth in Q3 FY26 on Oncology Network Strength
Feb 6, 2026
HealthCare Global Enterprises Ltd. reported its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, showing sustained growth in revenue and profitability. Consolidated revenue from operations rose 13% ...
HealthCare Global Board Clears Q3 and 9-Month FY26 Unaudited Results, Releases Investor Presentation
Feb 5, 2026
HealthCare Global Enterprises Ltd. announced that its Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and has released an accompanying investor pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.